Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing <i>Enterobacterales</i> in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020
Amelia Bhatnagar, Sandra Boyd, Sarah Sabour, Janine Bodnar, Elizabeth Nazarian, Nadine Peinovich, Wagner Christine, Bradley Craft, Paula Snippes Vagnone, Justin Simpson, Victoria Stone, Michelle C. S. Therrien, Allen Bateman, Danielle Lower, J. Huang, Stephanie Gumbis, David Lonsway, Joseph D. Lutgring, Maria Karlsson, Allison C. Brown
Abstract
Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution.
Topics & Concepts
AztreonamAntibioticsEnterobacteriaceae InfectionsMicrobiologyBeta-lactamMedicineCeftazidime/avibactamAntibiotic resistanceEnterobacteriaceaeBiologyGeneticsEscherichia coliGeneImipenemAntibiotic Resistance in BacteriaEnterobacteriaceae and Cronobacter ResearchPharmaceutical and Antibiotic Environmental Impacts